ESMO: Tell us a bit about your education and specialisation so far in your career
Jesus: I studied Medicine at the University of Seville in Spain and did a master in biomedical research and clinical trials. The topic of my research was based on translational medicine in advanced/metastatic non small cell lung cancer (IGFR pathway) and medullary thyroid cancer (RET mutated population). I completed my training with an observership in Lymphoma/Myeloma Department at the MD Anderson Cancer Center in Houston, Texas, and a clinical fellowship in the Drug Development Unit from the Royal Marsden Hospital in London.
What is your your current activity?
I am the Head of Thoracic Oncology at Clínica Universidad de Navarra, Madrid.
What are your plans for the future?
I am particularly focused in lung cancer early phase clinical trials and translational research.
Why did you choose to become a medical oncologist?
I decided to become a medical oncologist because I have always been interested in the care of patients with cancer and to try to understand the biology of the disease.
What does your involvement with ESMO and the Young Oncologists Committee (YOC) mean to you?
It is a pleasure for me to be involved with ESMO. I am sure ESMO-YOC is the perfect platform to be in contact with other young European medical oncologists and to work together to have a balanced and strong network. It is obvious, that I will try to obtain additional opportunities (fellowships, grants, visits) for my Spanish colleagues to allow them to improve their careers.
Do you have some good advice you would like to share with your international colleagues?
I think that in order to be a successful young medical oncologist, it is necessary to choose a qualified institution with excellent mentors around. It is mandatory to explore an experience abroad to complete your training (PhD, fellowship) and to meet other colleagues in prestigious and international courses and meetings (ESMO). Also, do not miss the opportunity to take part in the annual Flims Workshop ‘Methods in Clinical Cancer Research’.